Skip to search boxSkip to navigationSkip to main content

Characterization of a “low-risk” cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database

  • Kathleen F. McGinley
    ,
  • Xizi Sun
    ,
  • Lauren E. Howard
    ,
  • William J. Aronson
    ,
  • ,
  • Christopher J. Kane
*Corresponding author for this work
  • Duke University
    ,
  • Department of Veterans Affairs
    ,
  • University of California at Los Angeles
    ,
  • ,
  • University of California at San Diego
    ,
  • Oregon Health and Science University
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Objectives: To examine if there is a subset of men with grade group 2 prostate cancer who could be potential candidates for active surveillance. Methods: We used the Shared Equal Access Regional Cancer Hospital database to identify 776 men undergoing radical prostatectomy from 2006 to 2015 with >8 biopsy cores obtained and complete information. We compared men who fulfilled low-risk disease criteria (clinical stage T1c/T2a; grade group 1; prostate-specific antigen ≤10 ng/mL) with the exception of grade group 2 versus men who met all three low-risk criteria. Logistic regression was used to test the association between grade group and radical prostatectomy pathological features. Biochemical recurrence was examined using Cox models. To examine whether there was a subset of men with low-volume grade group 2 with comparable outcomes to low-risk men, we repeated all analyses limiting the percentage of positive cores in the grade group 2 group to ≤33%, and positive cores to ≤4, ≤3 or ≤2. Results: Grade group 2 low-risk men had increased risk of pathological grade group 3 or higher (P < 0.001), extraprostatic extension (P < 0.001), seminal vesicle invasion (P < 0.001) and higher risk of biochemical recurrence (hazard ratio = 1.76, P = 0.006). Using increasingly strict definitions of low-volume disease, at ≤2 positive cores there was no difference in adverse pathology between groups (all P > 0.2), except higher pathological grade group (P = 0.006). Biochemical recurrence was similar in men in grade group 1 and grade group 2 (hazard ratio = 1.24; P = 0.529). Conclusions: Among men with prostate-specific antigen ≤10 ng/mL and clinical stage T1c/T2a, those in grade group 2 with ≤2 total positive cores have similar rates of adverse pathology and biochemical recurrence as men with grade group 1.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 611-617 (7 pages)

Journal (Volume, Issue Number)

International Journal of Urology (Volume 24, Issue 8)

Publication milestones

  • Accepted/In press - 2017
  • Published - 08/2017

Publication status

Published - 08/2017

ISSN

0919-8172

Publication IDs

  • Scopus: 85020199637
  • PubMed: 28589550

Publication metrics

Metrics

SciVal
FWCI
0.13
SciVal
Author count
9
SciVal
citations
1
SciVal
Paper percentile
36
Fractional count
1
Fractional count
0.11
Fractional count
8
Fractional count
0.89
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
4
Captures
18

Funding Details

Research support was received from the NIH/NCI under award number P50CA09231 (William J Aronson) and NIH K24 CA160653 (Stephen J Freedland).
FundersFunding numbers
NIH K24 CA160653
K24 CA160653
NCI, NIH
P50CA09231
NCI
K24CA160653